Then after a year, they start going, I’m very comfortable with this. And then at 1.25 to 1.5 years, they actually start writing in the checkup exits, saying, hey, this dog is likely to get hip dysplasia at age seven. It’s something you should keep an eye on. And at the first signs, let’s talk about the use of Spryng. So it becomes a much-earlier-use product. And by Dr. Tammy Grubb making the statement that we should look at this as a frontline first-use product is very meaningful. And I’m not saying it’s going to replace NSAIDs. But it is a possibility of using it in conjunction as well as, also, we have seen in the real-world application, once Spryng is introduced, the need for NSAIDs is greatly reduced or eliminated. So just to give you a clue how big the NSAID market is, in the United States, it’s 385 million in the last reported year.
I just saw the numbers come out — I believe it was Grand View Research — for 2021. So moving on from there, we’re anticipating we’re going to get other types of articles that will come out or journal articles. And then going forward with MWI, having all this data will help us work with MWI to increase veterinary acceptance in the small animal side. And on the last call, we talked about the turnover at MWI, and that’s looking like we’re smoothing that out, and things are back in line. So we’re also going to be using a lot of increased social media focus. And what I mean by that is we’re going to be putting up a lot of actual real-world cases using Pinterest, Instagram, and so on. Because we find the amount of veterinary texts as well as the consumers — they’re reaching out to their vets.
And we’ve been really focusing on that because now — we did a news release. We’re in 47 states, and we’re starting to pick up good-size clinics in major cities. So we’re very comfortable now, having the consumer reach out to their vets. And then their vets are looking around their current area, and they’re finding other vets using the product. So that will really help us. And actually, we have been getting very good results recently with our social media. So I would now like to open the line up for questions. Operator?
Operator: [Operator Instructions]. Ms. Ribble.
Unidentified Analyst: I don’t know if anyone can hear me.
John Lai: I can hear you, but there’s a feedback.
Unidentified Analyst: Is that better?
John Lai: Yes, much better.
Unidentified Analyst: Oh, perfect. I’m just curious like — I know in the beginning of everything, and I’m new to this world. So thank you for putting up with my greenness. Just — we keep talking about a timeframe when they’re starting injecting smaller animals and blah, blah, blah. Just when is that exact timeframe is my — I’m just not clear on.
John Lai: Well, right now, veterinary doctors can buy the product, okay, for dogs and cats. We haven’t pushed on that side because we talked about all these clinical datas and presentations on the small animals in September, October coming out. So we feel that’s a big catalyst. But in the meantime, we’re seeing a lot of great results occurring in the dogs and the cat side. And in many of the larger cities, we have multiple clinics using our product. Does that help answer the question?
